• 1
    Clark DP. Seize the opportunity: underutilization of fine-needle aspiration biopsy to inform targeted cancer therapy decisions. Cancer. 2009; 117: 289-297.
  • 2
    Krishnamurthy S. Applications of molecular techniques to fine-needle aspiration biopsy. Cancer. 2007; 111: 106-122.
  • 3
    Shin HJ, Thorson P, Gu J, Katz RL. Detection of a subset of CD30+ anaplastic large cell lymphoma by interphase fluorescence in situ hybridization. Diagn Cytopathol. 2003; 29: 61-66.
  • 4
    Aiello A, Delia D, Giardini R, et al. PCR analysis of IgH and BCL2 gene rearrangement in the diagnosis of follicular lymphoma in lymph node fine-needle aspiration. A critical appraisal. Diagn Mol Pathol. 1997; 6: 154-160.
  • 5
    Bentz JS, Rowe LR, Anderson SR, Gupta PK, McGrath CM. Rapid detection of the t(11;14) translocation in mantle cell lymphoma by interphase fluorescence in situ hybridization on archival cytopathologic material. Cancer. 2004; 102: 124-131.
  • 6
    Caraway NP, Gu J, Lin P, Romaguera JE, Glassman A, Katz R. The utility of interphase fluorescence in situ hybridization for the detection of the translocation t(11;14)(q13;q32) in the diagnosis of mantle cell lymphoma on fine-needle aspiration specimens. Cancer. 2005; 105: 110-118.
  • 7
    Stelow EB, Policarpio-Nicolas ML, Sudduth KW, LeGallo RD. Burkitt lymphoma. Diagn Cytopathol. 2008; 36: 172-173.
  • 8
    Gautam U, Srinivasan R, Rajwanshi A, Bansal D, Marwaha RK, Vasishtha RK. Reverse transcriptase-polymerase chain reaction as an ancillary molecular technique in the diagnosis of small blue round cell tumors by fine-needle aspiration cytology. Am J Clin Pathol. 2010; 133: 633-645.
  • 9
    Roh MH, Dal Cin P, Silverman SG, Cibas ES. The application of cytogenetics and fluorescence in situ hybridization to fine-needle aspiration in the diagnosis and subclassification of renal neoplasms. Cancer (Cancer Cytopathol). 2010; 118: 137-145.
  • 10
    Caraway NP, Katz RL. A review on the current state of urine cytology emphasizing the role of fluorescence in situ hybridization as an adjunct to diagnosis. Cancer (Cancer Cytopathol). 2010; 118: 175-183.
  • 11
    Bofin AM, Ytterhus B, Martin C, O'Leary JJ, Hagmar BM. Detection and quantitation of HER-2 gene amplification and protein expression in breast carcinoma. Am J Clin Pathol. 2004; 122: 110-119.
  • 12
    Yassa L, Cibas ES, Benson CB, et al. Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation. Cancer. 2007; 111: 508-516.
  • 13
    Nikiforova MN, Nikiforov YE. Molecular diagnostics and predictors in thyroid cancer. Thyroid. 2009; 19: 1351-1361.
  • 14
    Nikiforov YE, Steward DL, Robinson-Smith TM, et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab. 2009; 94: 2092-2098.
  • 15
    Cantara S, Capezzone M, Marchisotta S, et al. Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J Clin Endocrinol Metab. 2010; 95: 1365-1369.
  • 16
    Moses W, Weng J, Sansano I, et al. Molecular testing for somatic mutations improves the accuracy of thyroid fine-needle aspiration biopsy. World J Surg. 2010; 34: 2589-2594.
  • 17
    Ohori NP, Nikiforova MN, Schoedel KE, et al. Contribution of molecular testing to thyroid fine-needle aspiration cytology of “follicular lesion of undetermined significance/atypia of undetermined significance.” Cancer (Cancer Cytopathol). 2010; 118: 17-23.
  • 18
    Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008; 26: 3543-3551.
  • 19
    Rekhtman N, Brandt SM, Sigel CS, et al. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol. 2011; 6: 451-458.
  • 20
    Mino-Kenudson M, Mark EJ. Reflex testing for epidermal growth factor receptor mutation and anaplastic lymphoma kinase fluorescence in situ hybridization in non-small cell lung cancer. Arch Pathol Lab Med. 2011; 135: 655-664.
  • 21
    Mukhopadhyay S, Katzenstein AL. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol. 2011; 35: 15-25.
  • 22
    Arkenau HT, Kefford R, Long GV. Targeting BRAF for patients with melanoma. Br J Cancer. 2011; 104: 392-398.
  • 23
    Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010; 363: 809-819.
  • 24
    Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011; 29: 1239-1246.
  • 25
    Hookim K, Roh MH, Willman J, et al. Application of immunocytochemistry and BRAF mutational analysis to direct smears of metastatic melanoma. Cancer (Cancer Cytopathol). 2012; 120: 52-61.
  • 26
    Betz BL, Roh MH, Weigelin HC, et al. The application of molecular diagnostic studies interrogating EGFR and KRAS mutations to stained cytologic smears of lung carcinoma. Am J Clin Pathol. 2011; 136: 564-571.
  • 27
    da Cunha Santos G, Liu N, Tsao MS, Kamel-Reid S, Chin K, Geddie WR. Detection of EGFR and KRAS mutations in fine-needle aspirates stored on Whatman FTA cards: is this the tool for biobanking cytological samples in the molecular era? Cancer (Cancer Cytopathol). 2010; 118: 450-456.
  • 28
    Ladd AC, O'Sullivan-Mejia E, Lea T, et al. Preservation of fine-needle aspiration specimens for future use in RNA-based molecular testing. Cancer (Cancer Cytopathol). 2011; 119: 102-110.
  • 29
    Killian JK, Walker RL, Suuriniemi M, et al. Archival fine-needle aspiration cytopathology (FNAC) samples: untapped resource for clinical molecular profiling. J Mol Diagn. 2010; 12: 739-745.
  • 30
    Roh MH, Schmidt L, Placido J, et al. The application and diagnostic utility of immunocytochemistry on direct smears in the diagnosis of pulmonary adenocarcinoma and squamous cell carcinoma [published online ahead of print April 15, 2011]. Diagn Cytopathol. doi: 10.1002/dc.21680.
  • 31
    Knoepp SM, Hookim K, Placido J, Fields KL, Roh MH. The application of immunocytochemistry to cytologic direct smears of metastatic merkel cell carcinoma [published online ahead of print December 5, 2011]. Diagn Cytopathol. doi: 10.1002/dc.22807.
  • 32
    Knoepp SM, Placido J, Fields KL, Thomas D, Roh MH. The application of immunocytochemistry to direct smears in the diagnosis of effusions [published online ahead of print April 30, 2012]. Diagn Cytopathol. doi: 10.1002/dc.22852.
  • 33
    Billah S, Stewart J, Staerkel G, Chen S, Gong Y, Guo M. EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens. Cancer (Cancer Cytopathol). 2011; 119: 111-117.
  • 34
    da Cunha Santos G, Saieg MA, Geddie W, Leighl N. EGFR gene status in cytological samples of nonsmall cell lung carcinoma: controversies and opportunities. Cancer (Cancer Cytopathol). 2011; 119: 80-91.
  • 35
    van Eijk R, Licht J, Schrumpf M, et al. Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR. PLoS One. 2011; 6: e17791.
  • 36
    Smith GD, Chadwick BE, Willmore-Payne C, Bentz JS. Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising high-resolution melting amplicon analysis. J Clin Pathol. 2008; 61: 487-493.